10:34 AM EDT, 10/02/2024 (MT Newswires) -- PharmAla Biotech Holdings ( MDXXF ) , manufacturer of LaNeo MDMA and novel derivatives of MDMA (MDXX class molecules), said Wednesday it has been contracted to supply MDMA to a clinical trial at Harvard's Maclean Hospital, which is described as the largest neuroscientific and psychiatric private research hospital in the world.

"As has recently been reported in the press, PharmAla has received numerous clinical trial inquiries and leads from key research organizations," said Nicholas Kadysh, CEO, PharmAla Biotech ( MDXXF ), in a statement. "We look forward to improving the lives of patients by providing high-quality MDMA to researchers in the US. We're also exploring mechanisms to pre-position some of our research materials in the US, in order to simplify our supply chain for these US trials."

PharmAla was last seen up $0.01, to $0.09, on the Canadian Securities Exchange.

Price: 0.09, Change: +0.01, Percent Change: +13.33